Dopavision Reports Successful Completion of Enrollment for MyopiaX-1 Trial
26 sept. 2023 04h00 HE
|
AKAMPION
- MyopiaX-1 trial to generate first clinical evidence with MyopiaX®, a novel therapeutic approach to manage myopia progression- First data readout expected in Q1/ 2024 with study completion planned...
Dopavision gibt Update zur klinischen Studie mit MyopiaX® bekannt; alle Studienzentren aktiv
28 juin 2023 04h00 HE
|
AKAMPION
- Klinische Erprobung von MyopiaX®, dem ersten Ansatz zur digitalen Behandlung von Kurzsichtigkeit bei Kindern beruhend auf dem Dopamin-Signalweg - Aufnahme von Patienten in Deutschland, Spanien,...
Dopavision proporciona información actualizada sobre los ensayos clínicos y anuncia que todos los centros del ensayo MyopiaX-1 están activos
28 juin 2023 04h00 HE
|
AKAMPION
- Primer ensayo clínico en humanos de MyopiaX® , el primer enfoque terapéutico para la miopía juvenil dirigido digitalmente a la vía dopaminérgica.- Inscripción en curso en Alemania, España, Países...
Dopavision Provides Clinical Trial Update and Announces All MyopiaX-1 Trial Sites Are Active
28 juin 2023 04h00 HE
|
AKAMPION
- First-in-human clinical trial of MyopiaX®, the first therapeutic approach in juvenile myopia to target the dopamine pathway digitally- Enrollment ongoing in Germany, Spain, the Netherlands, and the...
Dopavision Appoints Prof. Dr. Jens Ellrich as Chief Scientific Officer
21 mars 2023 05h00 HE
|
AKAMPION
- Leading translational medicine and neuroscience expert to head Dopavision’s research activities Berlin, Germany, March 21, 2023 --- Dopavision, a clinical-stage company pioneering the...
Dopavision Appoints Dr. Dirk Sauer as Chair of the Company's Advisory Board
16 nov. 2022 04h00 HE
|
AKAMPION
- Former Head of Novartis' Ophthalmology Development Unit to provide significant product development expertise and industry network Berlin, Germany, November 16, 2022 --- Dopavision, a...
Dopavision Appoints Mark S. Wuttke, Ph.D., as Chief Executive Officer
25 mai 2022 04h05 HE
|
AKAMPION
- Former Novartis ophthalmology program head significantly strengthens Dopavision´s management capabilities- Company recently initiated clinical trial of novel digital therapeutic for childhood myopia...